Drugs / GC022F CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04626908 | Nov 2020 → Jun 2022 | lymphoid hemopathy | He Huang | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC022F CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626908 ↗ |
| Modality | Cell therapy | “GC022F CAR-T cells” NCT04626908 ↗ |
| Target | CD19 | “Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes” NCT04626908 ↗ |
| Target | CD22 | “Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes” NCT04626908 ↗ |